Trial · NCT03287830
Flu2Text: Text Message Reminders for 2nd Dose of Influenza Vaccine
NCT03287830, Not applicable, Completed, Columbia University; results first posted 2023-03-14
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Flu2Text: Text Message Reminders for 2nd Dose of Influenza Vaccine. Trials, record NCT03287830. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03287830
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Flu2Text: Text Message Reminders for 2nd Dose of Influenza Vaccine
- NCT number
- NCT03287830
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 2,105 participants, actual
- Lead sponsor
- Columbia University
- Conditions
- Influenza, Vaccination
- Interventions
- Text message influenza vaccine reminders
- First posted
- 2017-09-19
- Last updated
- 2023-09-15
- Results first posted
- 2023-03-14
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percentage of Participants Who Receive Influenza Vaccination by April 30 Each Year | Up to receipt of second dose, an average of 6 months | Receipt of second dose influenza vaccine by the end of flu season, which is April 30 each year |
| Secondary | Percentage of Participants Who Receive a Second Vaccination by Day 42 From the Initial Influenza Vaccination | Up to 42 days after first dose | Receipt of second dose influenza vaccine by 42 days after first dose |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percentage of Participants Who Receive Influenza Vaccination by April 30 Each Year | Up to receipt of second dose, an average of 6 months | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Percentage of Participants Who Receive a Second Vaccination by Day 42 From the Initial Influenza Vaccination | Up to 42 days after first dose | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants Who Receive Influenza Vaccination by April 30 Each Year | Intervention | 875 | Participants | ||
| Percentage of Participants Who Receive Influenza Vaccination by April 30 Each Year | Usual Care | 843 | Participants | ||
| Percentage of Participants Who Receive a Second Vaccination by Day 42 From the Initial Influenza Vaccination | Intervention | 651 | Participants | ||
| Percentage of Participants Who Receive a Second Vaccination by Day 42 From the Initial Influenza Vaccination | Usual Care | 580 | Participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Intervention | 1,050 | |
| Overall Study | STARTED | Usual Care | 1,055 | |
| Overall Study | COMPLETED | Intervention | 1,044 | |
| Overall Study | COMPLETED | Usual Care | 1,042 | |
| Overall Study | NOT COMPLETED | Intervention | 6 | |
| Overall Study | NOT COMPLETED | Usual Care | 13 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Intervention | 0 | 1,044 |
| Total, all-cause mortality | Usual Care | 0 | 1,042 |
| Total, other adverse events | Intervention | 0 | 1,044 |
| Total, other adverse events | Usual Care | 0 | 1,042 |
| Total, serious adverse events | Intervention | 0 | 1,044 |
| Total, serious adverse events | Usual Care | 0 | 1,042 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 35965283 | DERIVED |
Source PubMed
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| R01HD086045 | Flu2Text: A Multi-Site Study assessing an Intervention for 2nd Dose of Influenza Vaccine | STOCKWELL, MELISSA S; FIKS, ALEXANDER GABRIEL | COLUMBIA UNIVERSITY HEALTH SCIENCES | EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT | 2016 to 2019 |
Source NIH RePORTER
Trial comparisons4
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Intervention vs Usual Care: Percentage of Participants Who Receive Influenza Vaccination by April 30 Each Year | Trial comparisons |
| Intervention vs Usual Care: deaths from any cause | Trial comparisons |
| Intervention vs Usual Care: Percentage of Participants Who Receive a Second Vaccination by Day 42 From the Initial Influenza Vaccination | Trial comparisons |
| Intervention vs Usual Care: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03287830
GET https://conductscience.org/api/trials/v1/NCT03287830/registered